Noah Editorial
Blog
Timely research perspectives, biotech market signals, and clinical updates in a cleaner long-form reading format.
September 24, 2026
•ComparisonBest AI Tools for Biomedical Research Question Feasibility Assessment (2026)
Compare AI tools for biomedical research question feasibility assessment in 2026, with a real Noah AI workflow evaluating novelty, biomarkers, recruitment, endpoints, and study design.
By Linda
September 24, 2026
•ComparisonBest AI Tools for Medical Literature Review and Evidence Synthesis (2026)
Compare the best AI tools for medical literature review and evidence synthesis in 2026, with a real Noah AI workflow across major NSCLC trials.
By Linda
September 24, 2026
•How-toHow to Conduct a Medical Literature Review with AI: Step-by-Step Guide
Learn how to conduct a medical literature review with AI step by step, using a real Noah AI workflow from research question to evidence table and synthesis.
By Linda
September 24, 2026
•How-toHow to Search PubMed for a Literature Review with AI: Step-by-Step Guide
Learn how to search PubMed for a literature review with AI, from MeSH terms and Boolean queries to search refinement and study selection using a real Noah AI workflow.
By Linda
September 24, 2026
•Research ProgressEmerging Immuno-Oncology Targets 2026: Beyond PD-1/PD-L1, Clinical Validation and Next-Wave Opportunities
Explore the 2026 immuno-oncology target landscape beyond PD-1/PD-L1, including validated targets, late-stage development programs, early clinical mechanisms, modality selection, tumor microenvironment biology, and a practical prioritization framework for research and strategy teams.
By Linda
September 24, 2026
•ComparisonSevere Asthma Indication Strategy Report 2026: TSLP Biology, Clinical Competition and Development Strategy
A 2026 severe asthma strategy report covering TSLP biology, unmet need, clinical validation, biologic competition, biomarker segmentation, and development strategy.
By Linda
September 24, 2026
•Comparison10 Biopharma Drugs to Watch in 2026: Regulatory Milestones, Phase 3 Readouts and What Comes Next
Track 10 biopharma drugs shaping 2026 through FDA and EC approvals, regulatory reviews, sponsor-reported Phase 3 topline results, launch milestones, and the next major catalysts.
By Linda
September 24, 2026
•How-toThe RAS Revolution in Pancreatic Cancer 2026: Targeted Therapy, Combination Strategies and Prevention
A 2026 review of RAS-targeted therapy in pancreatic cancer covering daraxonrasib, KRAS G12D and G12V strategies, phase 3 outcomes, combination therapy, synthetic lethality, and cancer interception.
By Linda
September 24, 2026
•How-toAI Agents for Biomedical Research: How Noah Turns Medical Evidence Into Research Workflows
Learn how Noah supports biomedical research workflows with PubMed Search, Health Search, multi-step Agent research, evidence synthesis, and structured cited outputs.
By Linda
September 22, 2026
•Use CasesCyclic Peptides in Drug Discovery 2026: Structures, Oral Bioavailability and Clinical Landscape
Explore cyclic peptide drug discovery in 2026, from cyclization chemistry and oral bioavailability to AI design, target opportunities, and the clinical pipeline.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Clinical Trial Eligibility Criteria Comparison (2026)
Compare AI tools for clinical trial eligibility criteria analysis, with a real Noah AI case across RASolute 305, 3082-CL-0301, and DAWN-303 in KRAS G12D metastatic pancreatic cancer.
By Linda
September 22, 2026
•ComparisonBest AI Tools for Clinical Trial Patient Population Comparison (2026)
Compare AI tools for clinical trial patient population analysis, with a real Noah AI case across DESTINY-Breast03, Breast04, and Breast06.
By Linda